Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis.

Leung TV, Hughes ME, Cambareri CG, Rubin DJ, Eaby-Sandy B.

J Adv Pract Oncol. 2018 Sep-Oct;9(6):614-629. Epub 2018 Sep 1. Review.

2.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME.

Oncologist. 2018 Aug;23(8):891-899. doi: 10.1634/theoncologist.2017-0582. Epub 2018 Apr 12. Review.

3.

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.

Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ.

Lung Cancer. 2017 Apr;106:1-7. doi: 10.1016/j.lungcan.2017.01.013. Epub 2017 Jan 25.

PMID:
28285682
4.

Use of Diagnostic Tests in Advanced Non-Small Cell Lung Cancer.

Eaby-Sandy B.

J Adv Pract Oncol. 2017 Mar;8(2):173-185. Epub 2017 Mar 1. Review.

5.

Swelling and Erythema of the Lower Extremities.

Eaby-Sandy B.

J Adv Pract Oncol. 2016 Jan-Feb;7(1):125-126. Epub 2016 Jan 1. Review. No abstract available.

6.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, VavalĂ  T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

7.

Side effects of targeted therapies: rash.

Eaby-Sandy B, Lynch K.

Semin Oncol Nurs. 2014 Aug;30(3):147-54. doi: 10.1016/j.soncn.2014.06.001. Review.

PMID:
25085026
8.

Side effects of targeted therapies. Introduction.

Eaby-Sandy B.

Semin Oncol Nurs. 2014 Aug;30(3):137-8. doi: 10.1016/j.soncn.2014.05.001. No abstract available.

PMID:
25085024
9.

Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group.

Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME.

Support Care Cancer. 2013 Oct;21(10):2933-48. doi: 10.1007/s00520-013-1896-2. Epub 2013 Aug 14. Review.

PMID:
23942595
10.

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.

Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A.

Cancer. 2012 Nov 15;118(22):5580-7. doi: 10.1002/cncr.27576. Epub 2012 Apr 27.

11.

Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.

Eaby-Sandy B, Grande C, Viale PH.

J Adv Pract Oncol. 2012 May;3(3):138-50. Review.

12.

A new targeted treatment for lung cancer patients.

Eaby-Sandy B.

J Adv Pract Oncol. 2012 Mar;3(2):103-6. Review. No abstract available.

13.

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group.

Support Care Cancer. 2011 Aug;19(8):1079-95. doi: 10.1007/s00520-011-1197-6. Epub 2011 Jun 1. Review.

Supplemental Content

Loading ...
Support Center